Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person The IL1 family includes two agonists, IL1α and IL1β, and a n...
| Class:Id | Summation:9681752 |
|---|---|
| _displayName | The IL1 family includes two agonists, IL1α and IL1β, and a n... |
| _timestamp | 2020-06-02 10:05:40 |
| created | [InstanceEdit:9681760] Jassal, Bijay, 2020-04-06 |
| literatureReference | [LiteratureReference:9681776] Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial [LiteratureReference:9681777] Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial [LiteratureReference:9681746] Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases [LiteratureReference:9681790] Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis [LiteratureReference:9685656] The Rheumatologist's Role in COVID-19 |
| modified | [InstanceEdit:9685657] Jassal, Bijay, 2020-04-24 [InstanceEdit:9690514] Jassal, Bijay, 2020-06-02 |
| text | The IL1 family includes two agonists, IL1α and IL1β, and a naturally occurring receptor antagonist, IL1Ra. IL1Ra is produced locally in various tissues in response to infection or inflammation (Arend & Gabay 2000). Anakinra (Kineret) is a recombinant form of IL1Ra that competitively inhibit the local inflammatory effects of IL1 (Seckinger et al. 1990) and is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate (Drevlow et al. 1996, Cohen et al. 2002, Fleischmann et al. 2003). Isunakinra (EBI 005) is a fusion protein containing domains from IL1β and the IL1 receptor antagonist (IL1Ra or anakinra) developed as a topical therapy for dry eye disease (Goldstein et al. 2017). It blocks IL1R1 signalling with higher affinity than anakinra (Kovalchin et al. 2018). These IL1R1 inhibitors may be investigated for their role in blocking inflammatory cytokines produced in the "cytokine storm syndrome" caused by COVID-19 (Cron & Chatham 2020). |
| (summation) | [Reaction:9681763] IL1R1 binds IL1R1 inhibitors [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by The IL1 family includes two agonists, IL1α and IL1β, and a n... (9681752)
